GEN Exclusives

More »

GEN News Highlights

More »
May 29, 2007

Valeant Taps Parexel to Assist with Epilepsy Drug Regulatory Applications

  • Valeant Pharmaceuticals appointed Parexel to develop, coordinate, and prepare the NDA and the European MAA for its investigational compound retigabine. This candidate is a neuronal potassium-channel opener that is being studied in Phase III trials as an adjunctive treatment for partial-onset seizures in patients with epilepsy.

    "Parexel's regulatory expertise is anticipated to play a critical role in our development of retigabine," says Wesley P. Wheeler, Valeant's president North America and R&D. "Parexel's global presence and long experience with NDA and MAA filings will be invaluable in the regulatory filing process for retigabine."

    Valeant anticipates filing the NDA and MAA for retigabine in mid-2008.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »